Valiance Asset Management

JenaValve Technology, Inc., established in 2006, specializes in developing and manufacturing transcatheter aortic valve replacement (TAVR) systems. Its flagship product, the Trilogy™ Heart Valve System, is designed to treat high-risk patients with symptomatic, severe aortic regurgitation and aortic stenosis. The system, which received CE Mark approval in 2021, features a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame with integral locators that engage with the native valve cusps. JenaValve operates globally, with headquarters in Irvine, California, and additional locations in Munich, Germany, and Leeds, United Kingdom.

Laminate Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, founded in 2012. The company focuses on improving vascular access for hemodialysis patients through its innovative product, the VasQ device. This implanted blood vessel external support device is designed to be used during the creation of arteriovenous fistulas, addressing issues such as wall tension and undesired narrowing of veins that can lead to complications within the first year. By enhancing the geometry of the fistula and reducing the risk of blockages, VasQ aims to significantly lower the annual fistula failure rate. This advancement seeks to transform the treatment landscape for hemodialysis patients, minimizing kidney-failure related complications and the associated costs of re-interventions and vascular access complications.

MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

FEops is a pioneer in physics-based simulations specifically tailored for minimally invasive cardiovascular devices and procedures. The company develops advanced cardiac imaging technology that enhances personalized treatment for patients with structural heart disease. By utilizing artificial intelligence to conduct anatomical analyses, FEops provides data-driven insights that improve transcatheter valve procedures through personalized computer simulations. This approach offers medical device companies and healthcare professionals unique insights that streamline research and development processes, enhance procedural efficiency, and ultimately improve clinical outcomes and patient safety. Additionally, FEops supports medical specialists and physicians with patient-specific information, facilitating more effective treatments.

NeoSync is a clinical-stage company focused on developing advanced, non-invasive neuromodulation products aimed at treating Major Depressive Disorder and various Central Nervous System diseases, including Autism, Parkinson's Disease, Anxiety, and Post Traumatic Stress Disorder. The company utilizes a proprietary platform technology that employs Transcranial Magnetic Stimulation (TMS), a non-invasive brain stimulation method delivering low-energy, alternating magnetic field stimulation during daily 30-minute sessions. This approach is designed to gently adjust the brain's activity, helping patients recover from major depressive disorders and other related conditions more effectively. Led by a team of experienced medical device executives and entrepreneurs, NeoSync is committed to delivering personalized therapies that address significant mental health challenges.

JenaValve Technology, Inc., established in 2006, specializes in developing and manufacturing transcatheter aortic valve replacement (TAVR) systems. Its flagship product, the Trilogy™ Heart Valve System, is designed to treat high-risk patients with symptomatic, severe aortic regurgitation and aortic stenosis. The system, which received CE Mark approval in 2021, features a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame with integral locators that engage with the native valve cusps. JenaValve operates globally, with headquarters in Irvine, California, and additional locations in Munich, Germany, and Leeds, United Kingdom.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced epigenetic tests to assist in the detection and treatment of cancer. The company's product portfolio includes ConfirmMDx, a prostate cancer test aimed at addressing false-negative biopsy concerns; SelectMDx, which guides repeat biopsies for prostate cancer; AssureMDx, a noninvasive liquid biopsy test for bladder cancer; and PredictMDx for Glioblastoma, a tissue methylation test that aids in treatment decisions for brain cancer. Established in 2003 and headquartered in Irvine, California, with additional offices in Belgium and the Netherlands, MDxHealth leverages proprietary genomic and epigenetic technologies to provide actionable diagnostic information. The company's revenue is generated through clinical laboratory services and out-licensing of its patented DNA methylation platform and biomarkers, serving markets primarily in the United States and Europe.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.